ReviewAutoimmunity reviews2007
Moving towards efficient therapies in type 1 diabetes: to combine or not to combine?
Review in Autoimmunity reviews, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 60 citations in OpenAlex.
- Type 1 Diabetes Mellitus and Autoimmune Diseases: A Critical Review of the Association and the Application of Personalized Medicine.Journal of personalized medicine · 2023Review
- Immunomodulatory Dual-Sized Microparticle System Conditions Human Antigen Presenting Cells Into a Tolerogenic PhenotypeFrontiers in immunology · 2020Article
- Self-Transducible Bimodal PDX1-FOXP3 Protein Lifts Insulin Secretion and Curbs Autoimmunity, Boosting Tregs in Type 1 Diabetic Mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Clinical Tolerogenic Dendritic Cells: Exploring Therapeutic Impact on Human Autoimmune Disease.Frontiers in immunology · 2017Review
- Naturally occurring anthraquinones: chemistry and therapeutic potential in autoimmune diabetes.Evidence-based complementary and alternative medicine : eCAM · 2015Review
- Involvement of suppressive B-lymphocytes in the mechanism of tolerogenic dendritic cell reversal of type 1 diabetes in NOD mice.PloS one · 2014Article
- Structure modeling and antidiabetic activity of a seed protein of Momordica charantia in non-obese diabetic (NOD) mice.Bioinformation · 2013Article
- Amelioration of type 1 diabetes following treatment of non-obese diabetic mice with INGAP and lisofylline.Journal of diabetes mellitus · 2012Article
- Suppressive effects of natural reduced waters on alloxan-induced apoptosis and type 1 diabetes mellitus.Cytotechnology · 2012Article
- Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment.Journal of autoimmunity · 2011Article
- Stem cell therapy for diabetes mellitus.Kidney international supplements · 2011Review
- Suppressive effects of electrolyzed reduced water on alloxan-induced apoptosis and type 1 diabetes mellitus.Cytotechnology · 2011Article
- Anti-thymoglobulin (ATG) treatment does not reverse type 1 diabetes in the acute virally induced rat insulin promoter-lymphocytic choriomeningitis virus (RIP-LCMV) model.Clinical and experimental immunology · 2011Article
- Humanizing animal models: a key to autoimmune diabetes treatment.Science translational medicine · 2011Article
- Antigen-based immune therapeutics for type 1 diabetes: magic bullets or ordinary blanks?Clinical & developmental immunology · 2011Article
- Expression level of a pancreatic neo-antigen in beta cells determines degree of diabetes pathogenesis.Journal of autoimmunity · 2010Article
- Subcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNgamma.Diabetologia · 2010Article
- Gene therapy in diabetes.Self/nonself · 2010Article
- Banting Lecture 2009: An unfinished journey: molecular pathogenesis to prevention of type 1A diabetes.Diabetes · 2010Article
- Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Every year, thirty thousand people worldwide are diagnosed with type 1 diabetes mellitus (T1DM). T1DM, also called autoimmune diabetes, is a multifactorial disease affecting predisposed individuals and involving genetic susceptibilities, environmental triggers, as well as unbalanced immune responses. Auto-reactive T cells, produced during the pathogenesis, play an important role by specifically destroying the pancreatic insulin-producing beta-cells in the islets of Langerhans. Numerous therapeutic interventions have been tested, mostly in animal models, but also in humans. To date, only three phase II/III clinical trials have demonstrated safety and efficacy: anti-CD3 antibody, DiaPep277, and GAD65 (in patients with latent autoimmune diabetes in adults). Unfortunately, a significant number of patients did not respond positively and remained insulin-dependent after completion of therapy. Several reasons account for this. Firstly, the severity of the disease as well as the auto-aggressive T cell repertoire vary from patient to patient leading to a broad range of therapeutic efficacies, and secondly at the time of the treatment the number of remaining beta-cells will directly impact the level of insulin production post-treatment. In this review, we will provide some clues to enhance efficacy of future immuno-interventions in patients with T1DM. We suggest that combination therapies might be the best approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.